Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

ABSTRACT:

Background

The development of brain metastases is common for systemic treatment failure in patients with melanoma and has been associated with a poor prognosis. Recent advances with BRAF and immune checkpoint therapies have led to improved patient survival. Herein, the authors evaluated the risk of de novo brain metastases and survival among patients with melanoma brain metastases (MBM) since the introduction of more effective therapies.

Methods

Patients with unresectable AJCC stage III/IV melanoma who received first-line systemic therapy at Moffitt Cancer Center between 2000 and 2012 were identified. Data were collected regarding patient characteristics, stage of disease, systemic therapies, MBM status/management, and overall survival (OS). The risk of de novo MBM was calcu

SUBMITTER: Sloot S 

PROVIDER: S-EPMC7771556 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature